These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19199893)

  • 1. Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review.
    Gálvez MI
    Curr Diabetes Rev; 2009 Feb; 5(1):14-7. PubMed ID: 19199893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
    ; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
    Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Davis MD; Sheetz MJ; Aiello LP; Milton RC; Danis RP; Zhi X; Girach A; Jimenez MC; Vignati L;
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
    Sahu AK; Majji AB
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6890; author reply 6890-1. PubMed ID: 21123772
    [No Abstract]   [Full Text] [Related]  

  • 5. The potential role of PKC beta in diabetic retinopathy and macular edema.
    Aiello LP
    Surv Ophthalmol; 2002 Dec; 47 Suppl 2():S263-9. PubMed ID: 12507628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
    Sheetz MJ; Aiello LP; Davis MD; Danis R; Bek T; Cunha-Vaz J; Shahri N; Berg PH;
    Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):1750-7. PubMed ID: 23404115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
    Aiello LP; Vignati L; Sheetz MJ; Zhi X; Girach A; Davis MD; Wolka AM; Shahri N; Milton RC;
    Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of diabetic retinopathy with protein kinase C subtype Beta inhibitor.
    Lang GE
    Dev Ophthalmol; 2007; 39():157-165. PubMed ID: 17245085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors.
    Frank RN
    Am J Ophthalmol; 2002 May; 133(5):693-8. PubMed ID: 11992868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
    PKC-DRS Study Group
    Diabetes; 2005 Jul; 54(7):2188-97. PubMed ID: 15983221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medications for diabetic macular edema].
    Kitano S
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():275-9. PubMed ID: 15999719
    [No Abstract]   [Full Text] [Related]  

  • 12. Ruboxistaurin for diabetic retinopathy.
    Gardner TW; Antonetti DA
    Ophthalmology; 2006 Dec; 113(12):2135-6. PubMed ID: 17157131
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
    PKC-DMES Study Group
    Arch Ophthalmol; 2007 Mar; 125(3):318-24. PubMed ID: 17353401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
    Strøm C; Sander B; Klemp K; Aiello LP; Lund-Andersen H; Larsen M
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3855-8. PubMed ID: 16186374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C inhibitors in the treatment of diabetic retinopathy. Review.
    Gálvez MI
    Curr Pharm Biotechnol; 2011 Mar; 12(3):386-91. PubMed ID: 20939796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic macular oedema and visual loss: relationship to location, severity and duration.
    Gardner TW; Larsen M; Girach A; Zhi X;
    Acta Ophthalmol; 2009 Nov; 87(7):709-13. PubMed ID: 19817721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruboxistaurin: LY 333531.
    Drugs R D; 2007; 8(3):193-9. PubMed ID: 17472415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
    Sheetz MJ; Aiello LP; Shahri N; Davis MD; Kles KA; Danis RP;
    Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruboxistaurin mesilate hydrate for diabetic retinopathy.
    Schwartz SG; Flynn HW; Aiello LP
    Drugs Today (Barc); 2009 Apr; 45(4):269-74. PubMed ID: 19499092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research.
    Donnelly R; Idris I; Forrester JV
    Br J Ophthalmol; 2004 Jan; 88(1):145-51. PubMed ID: 14693793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.